ABSTRACT
Ga-68 prostate specific membrane antigens positron emission tomography/computerized tomography (PSMA PET/CT) imaging has shown outstanding results in the staging and restaging of prostate cancer and has taken its place in guidelines. However, the value in the assessment of treatment response has not yet been determined. The criteria by “Prostate cancer clinical trial working group” has been used to evaluate the treatment response of prostate cancer. However, the results of clinical trials based on these criteria are likely to be unreliable. Furthermore, the data we have are very limited and do not seem to be comparable due to both the treatments applied and the biological status of the disease. There is also a debate on clinical progression under treatment. The importance of timing for post-treatment scan and findings in treatment response should be defined with standardization and more studies are needed to determine the place of Ga-68 PSMA PET/CT in the evaluation of treatment response.